
Genzyme appoints new GM for UK and Ireland
pharmafile | November 29, 2012 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Brendan Martin, Genzyme
Genzyme has announced the appointment of Brendan Martin as general manager for UK and Ireland.
Martin will be responsible for all Genzyme’s commercial activities in the UK and Ireland and will report to Robin Kenselaar, head of Genzyme EMEA.
Martin joined Genzyme in 2002 and was responsible for establishing and developing Genzyme’s Lysosomal Storage Disorders business in Ireland. In 2007, he became Business Unit director and, in 2010, deputy general manager for UK and Ireland. He will be leading Genzyme in the UK and Ireland which will now, as part of the Sanofi group, focus on rare inherited diseases and immune diseases.
Martin’s appointment follows the decision of Paul Drohan, senior VP and general manager UK and Ireland, to leave Genzyme following a 17-year career with the company to return to Canada and pursue other opportunities.
Robin Kenselaar, head of Genzyme EMEA said: “Brendan’s appointment as general manager UK and Ireland comes at a key time for the business as it builds its multiple sclerosis franchise and continues to develop in rare diseases. In his Genzyme career to date, Brendan has shown he is a leader with the experience, energy, vision and commitment to patients needed to move us forward.”
Related Content

Use of Genzyme’s MS drug Lemtrada restricted under ongoing EMA safety review
The EMA has launched a review into Genzyme’s multiple sclerosis drug Lemtrada (alemtuzumab) after reports …

Alnylam and Sanofi close research phase of 2014’s $700m RNAi rare disease partnership
Alnylam and Sanofi have announced their intention to bring to an end the research and …

Cancer drugs prices vary up to 388% between high-income countries
The price of new cancer drugs varies widely between high-income countries in Europe, Australia, and …






